The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Our global portfolio comprises approximately 1 000 molecules, covering a wide range of therapeutic areas, which accounted for 2021 sales of USD 9.6 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach approximately 500 million patients every year. Our broad portfolio is spearheaded by our global leadership positions in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the backbone of global healthcare systems.
To learn more visit https://www.sandoz.com/